C-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma

Journal of Pathology

Volumn 237, Issue 3, 2015, Pages 319-329

  Zhao, Lan ^a   Wu, Yan ^a   Xie, Xu Dong ^a   Chu, Yi Fan ^a   Li, Jin Qing ^a   Zheng, Limin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

c Met; hepatocellular carcinoma (HCC); matrix metalloproteinase (MMP) 9; monocyte

Indexed keywords

GELATINASE B; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12P70; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HEMANGIOMA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; AUTOCRINE EFFECT; CELL MOTION; COCULTURE; ENZYMOLOGY; HEPG2 CELL LINE; KAPLAN MEIER METHOD; LIVER TUMOR; MACROPHAGE; MACROPHAGE ACTIVATION; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; STROMA CELL; TIME FACTOR;

ANIMALS; AUTOCRINE COMMUNICATION; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; COCULTURE TECHNIQUES; FEMALE; HEP G2 CELLS; HEPATOCYTE GROWTH FACTOR; HLA-DR ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MICE, NUDE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; STROMAL CELLS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945465803     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4578     Document Type: Article

References (44)

1. Lewis CE, Pollard JW,. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66: 605-612.
2. De Palma M, Lewis CE,. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 2013; 23: 277-286.
3. Thomson AW, Knolle PA,. Antigen-presenting cell function in the tolerogenic liver environment. Nature Rev Immunol 2010; 10: 753-766.
4. Jaiswal S, Chao MP, Majeti R, et al., Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010; 31: 212-219.
5. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nature Rev Immunol 2008; 8: 958-969.
6. Murdoch C, Muthana M, Coffelt SB, et al., The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev Cancer 2008; 8: 618-631.
7. Qian BZ, Pollard JW,. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
8. Mantovani A, Sozzani S, Locati M, et al., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
9. Sica A, Invernizzi P, Mantovani A,. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 2014; 59: 2034-2042.
10. Martinez FO, Helming L, Gordon S,. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483.
11. Budhu A, Forgues M, Ye QH, et al., Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
12. Kuang DM, Wu Y, Chen N, et al., Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007; 110: 587-595.
13. Kuang DM, Zhao Q, Peng C, et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206: 1327-1337.
14. Hernandez ED, Lee SJ, Kim JY, et al., A macrophage NBR1-MEKK3 complex triggers JNK-mediated adipose tissue inflammation in obesity. Cell Metab 2014; 20: 499-511.
15. Hui LJ, Zatloukal K, Scheuch H, et al., Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118: 3943-3953.
16. Ke B, Shen XD, Kamo N, et al., Beta-catenin regulates innate and adaptive immunity in mouse liver ischemia-reperfusion injury. Hepatology 2013; 57: 1203-1214.
17. Yan B, Wei JJ, Yuan Y, et al., IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation. J Immunol 2013; 190: 5882-5893.
18. Nejak-Bowen KN, Thompson MD, Singh S, et al., Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine-45 mutant beta-catenin. Hepatology 2010; 51: 1603-1613.
19. Sui Q, Zhang J, Sun X, et al., NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma. J Immunol 2014; 193: 2016-2023.
20. Wang P, Xue YQ, Han YM, et al., The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science 2014; 344: 310-313.
21. Yu H, Pardoll D, Jove R,. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Rev Cancer 2009; 9: 798-809.
22. Cao Y, Zhang L, Ritprajak P, et al., Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. Cancer Res 2011; 71: 4737-4741.
23. Ding ZC, Lu X, Yu M, et al., Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res 2014; 74: 3441-3453.
24. Goyal L, Muzumdar MD, Zhu AX,. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 2013; 19: 2310-2318.
25. Koeppen H, Rost S, Yauch RL,. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors. J Pathol 2014; 232: 210-218.
26. Gherardi E, Birchmeier W, Birchmeier C, et al., Targeting MET in cancer: rationale and progress. Nature Rev Cancer 2012; 12: 89-103.
27. Birchmeier C, Birchmeier W, Gherardi E, et al., Met, metastasis, motility and more. Nature Rev Mol Cell Biol 2003; 4: 915-925.
28. Nagai T, Arao T, Furuta K, et al., Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma. Mol Cancer Ther 2011; 10: 169-177.
29. Giordano S, Columbano A,. Met as a therapeutic target in HCC: facts and hopes. J Hepatol 2014; 60: 442-452.
30. Trusolino L, Bertotti A, Comoglio PM,. Met signalling: principles and functions in development, organ regeneration and cancer. Nature Rev Mol Cell Biol 2010; 11: 834-848.
31. Vakkila J, Lotze MT,. Opinion-inflammation and necrosis promote tumour growth. Nature Rev Immunol 2004; 4: 641-648.
32. Neaud V, Faouzi S, Guirouilh J, et al., Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997; 26: 1458-1466.
33. Gao B, Jeong WI, Tian Z,. Liver: an organ with predominant innate immunity. Hepatology 2008; 47: 729-736.
34. Furlan A, Kherrouche Z, Montagne R, et al., Thirty years of research on Met receptor to move a biomarker from bench to bedside. Cancer Res 2014; 74: 6737-6744.
35. Baek JH, Birchmeier C, Zenke M, et al., The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J Immunol 2012; 189: 1699-1707.
36. Liu X, Yao W, Newton RC, et al., Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008; 17: 997-1011.
37. Moransard M, Sawitzky M, Fontana A, et al., Expression of the HGF receptor c-met by macrophages in experimental autoimmune encephalomyelitis. Glia 2010; 58: 559-571.
38. Beilmann M, Vande Woude GF, Dienes HP, et al., Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood 2000; 95: 3964-3969.
39. Kuang DM, Zhao Q, Wu Y, et al., Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol 2011; 54: 948-955.
40. Mueller MM, Fusenig NE,. Friends or foes-bipolar effects of the tumour stroma in cancer. Nature Rev Cancer 2004; 4: 839-849.
41. Arii S, Mise M, Harada T, et al., Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996; 24: 316-322.
42. Kuang DM, Peng C, Zhao Q, et al., Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010; 51: 154-164.
43. H17 cells in tumour immunity and immunotherapy. Nature Rev Immunol 2010; 10: 248-56.
44. Hack SP, Bruey JM, Koeppen H,. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014; 5: 2866-2880.